MOBERG PHARMA’S NOMINATION COMMITTEE APPOINTED
In accordance with the resolution of the Annual General Meeting on May 13, 2014, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee. As not all of the company’s three largest shareholders or group of shareholders have wished to appoint such representative, the forth largest shareholder/group of shareholders have been invited to appoint one representative and so on until the Nomination Committee now comprises of four members, in accordance with the resolution of the Annual General Meeting on May 13.
Moberg Pharma’s Nomination Committee ahead of the 2015 Annual General Meeting comprises:
- Mats Petterson, Chairman of the Board
- Per-Olof Edin, appointed by Östersjöstiftelsen
- George E. Aitken-Davies, appointed by Altaris Capital Partners (JPM Chase NA)
- Ulrica Slåne Sens, appointed by Tredje AP-fonden
Per-Olof Edin has been appointed Chairman of the Nomination Committee. Together, the Nomination Committee represents 26.7 percent of the shares in Moberg Pharma as of September 30, 2014.
The Nomination Committee shall submit proposals for resolution by the 2015 Annual General Meeting pertaining to the election of Chairman of the Board, fees and composition of the Board, auditors’ fees and the election of auditors.
The 2015 Annual General Meeting will be held in Stockholm on May 11.
Shareholders wishing to submit proposals to Moberg Pharma’s Nomination Committee can do so by e-mail to firstname.lastname@example.org by 31 December 2014.
For further information, please contact:
Peter Wolpert, CEO
Telephone: +46 8 522 307 00; Mobile: +46 707 35 71 35; E-mail: email@example.com
Peter Östling, IR
Telephone: +46 76 314 0978; Email: firstname.lastname@example.org
About Moberg Pharma AB
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with a direct sales and marketing organization in the U.S. and an extensive distributor network in more than 40 countries. The company’s OTC portfolio includes the brands Kerasal®, Jointflex®, Kerasal Nail®, Domeboro®, Vanquish®, and Fergon®. Kerasal Nail® (Nalox™ in certain ex-U.S. markets) is the leading product for the treatment of nail disorders in the U.S. and Nordic market. The current portfolio will be supplemented by the acquisition and in-licensing of additional products as well as product development with a focus on innovative drug delivery of proven compounds. Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares (OMX: MOB) are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergpharma.com.